Fig. 3: T-αFGL2 treatment induced brain-resident tumor-specific memory T cells.

a Schematic of rechallenge with tumor cells. On day 70 after first tumor cell inoculation, T-αFGL2–treated survivors bearing orthotopic DBT gliomas were rechallenged with DBT cells injected either subcutaneously (s.c.) or intracranially (i.c.). b Kaplan–Meier survival curves (left) and representative bioluminescence images (right) of mice in (a) on day 0 and day 7 after second tumor cell inoculation (i.c.) (n = 6 mice). ***P = 0.0005, log-rank test. c Tumor volume (left) and representative bioluminescence images (middle) of mice on day 0 and day 7 after second tumor cell inoculation (s.c.), and representative tumors (right) collected on day 11 after second tumor cell inoculation (s.c.) from the flanks of Balb/c mice (n = 3 mice/group; data are mean ± SD). d Representative flow cytometry plots depicting increase of CD8⁺ T cells in the brains (BIL) of long-term survivors treated with T-αFGL2 (T-αFGL2 survivor). LN lymph node. e Ratio of CD8⁺ T cells to CD4⁺ T cells in the brains of naïve mice and T-αFGL2 survivors and the LNs of T-αFGL2 survivors. Data are mean ± SD, one-way ANOVA with Tukey’s test for comparing multiple treatments. f CD8⁺ T cell numbers in the brains of naïve mice and T-αFGL2 survivors (n = 3 naïve mice, n = 5 T-αFGL2 survivors; data are mean ± SD), two-tailed t-test. The experiments were repeated three times with similar results.